0001070081-18-000056.txt : 20180621 0001070081-18-000056.hdr.sgml : 20180621 20180621163304 ACCESSION NUMBER: 0001070081-18-000056 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180619 FILED AS OF DATE: 20180621 DATE AS OF CHANGE: 20180621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Almstead Neil Gregory CENTRAL INDEX KEY: 0001578850 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 18912142 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 wf-form4_152961316540176.xml FORM 4 X0306 4 2018-06-19 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001578850 Almstead Neil Gregory C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 EVP Research Pharma Ops & Tech Common Stock 2018-06-19 4 M 0 20000 10.85 A 37154 D Common Stock 2018-06-19 4 S 0 8000 48.09 D 29154 D Common Stock 2018-06-19 4 S 0 12000 48.46 D 17154 D Common Stock 5125 I By spouse Stock Option (Right To Buy) 10.85 2018-06-19 4 M 0 20000 10.85 D 2023-05-15 Common Stock 20000.0 46898 D Stock Option (Right To Buy) 451.2 2019-05-15 Common Stock 200.0 200 D Stock Option (Right To Buy) 1149.6 2020-02-02 Common Stock 200.0 200 D Stock Option (Right To Buy) 490.8 2021-04-27 Common Stock 216.0 216 D Stock Option (Right To Buy) 218.4 2022-01-10 Common Stock 166.0 166 D Stock Option (Right To Buy) 10.85 2023-05-15 Common Stock 3102.0 3102 D Stock Option (Right To Buy) 27.05 2024-01-27 Common Stock 40000.0 40000 D Stock Option (Right To Buy) 51.0 2025-01-01 Common Stock 69550.0 69550 D Stock Option (Right To Buy) 30.86 2026-01-03 Common Stock 55000.0 55000 D Stock Option (Right To Buy) 11.23 2027-01-02 Common Stock 35000.0 35000 D Stock Option (Right To Buy) 18.01 2028-01-02 Common Stock 70000.0 70000 D Stock Option (Right To Buy) 508.8 2019-10-07 Common Stock 12.0 12 I By spouse Stock Option (Right To Buy) 1149.6 2020-02-02 Common Stock 1.0 1 I By spouse Stock Option (Right To Buy) 490.8 2021-04-27 Common Stock 7.0 7 I By spouse Stock Option (Right To Buy) 218.4 2022-01-10 Common Stock 7.0 7 I By spouse Stock Option (Right To Buy) 27.05 2024-01-27 Common Stock 1300.0 1300 I By spouse Stock Option (Right To Buy) 51.0 2025-01-01 Common Stock 2060.0 2060 I By spouse The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.58 to $48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.38 to $48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable. This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016. This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. /s/ Avraham S. Adler, attorney-in-fact 2018-06-21